Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Net Cash Flow (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Net Cash Flow data on record, last reported at -$2.4 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 9.83% year-over-year to -$2.4 million; the TTM value through Dec 2025 reached $3.5 million, up 157.81%, while the annual FY2025 figure was $4.5 million, 292.42% up from the prior year.
  • Net Cash Flow reached -$2.4 million in Q4 2025 per INM's latest filing, down from -$1.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $8.0 million in Q3 2021 and bottomed at -$5.4 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$252946.8, with a median of -$1.4 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: tumbled 348.26% in 2023, then soared 721.59% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$4.1 million in 2021, then skyrocketed by 164.03% to $2.6 million in 2022, then tumbled by 171.02% to -$1.8 million in 2023, then fell by 17.07% to -$2.2 million in 2024, then fell by 9.83% to -$2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$2.4 million in Q4 2025, -$1.7 million in Q3 2025, and $6.4 million in Q2 2025.